87. The method of claim **76**, further comprising performing steps (a) and (b) a second time to determine the antigenic stability of the antigen over time.

88. The method of claim **76**, further comprising:

(c) contacting a sample comprising said antigen with a second antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively; and

(d) determining antigenic integrity of said antigen by detectable binding of said second antibody or antibody fragment to said antigen.

89. The method of claim **88**, wherein the second antibody or antibody fragment is encoded by clone-paired variable sequences as set forth in Table 1.

90. The method of claim **89**, wherein said second antibody or antibody fragment is encoded by light and heavy chain variable sequences having 70%, 80%, or 90% identity to clone-paired variable sequences as set forth in Table 1.

91. The method of claim **89**, wherein said second antibody or antibody fragment is encoded by light and heavy chain variable sequences having 95% identity to clone-paired sequences as set forth in Table 1.

92. The method of claim **89**, wherein said second antibody or antibody fragment comprises light and heavy chain variable sequences according to clone-paired sequences from Table 2.

93. The method of claim **89**, wherein said second antibody or antibody fragment comprises light and heavy chain variable sequences having 70%, 80% or 90% identity to clone-paired sequences from Table 2.

94. The method of claim **89**, wherein said second antibody or antibody fragment comprises light and heavy chain variable sequences having 95% identity to clone-paired sequences from Table 2.

95. The method of claim **89**, wherein the second antibody fragment is a recombinant scFv (single chain fragment variable) antibody, Fab fragment, F(ab')2 fragment, or Fv fragment.

96. The method of claim **89**, further comprising performing steps (c) and (d) a second time to determine the antigenic stability of the antigen over time.

97. A human monoclonal antibody or antibody fragment, or hybridoma or engineered cell producing the same, wherein said antibody or antibody fragment binds to norovirus capsid protein P domain and/or S domain.

98. The human monoclonal antibody or antibody fragment, or hybridoma or engineered cell producing the same, of claim **97**, wherein said antibody or antibody fragment binds to norovirus capsid protein P domain but not norovirus capsid protein S domain.

99. The human monoclonal antibody or antibody fragment, or hybridoma or engineered cell producing the same, of claim **97**, wherein said antibody or antibody fragment binds to norovirus capsid protein S domain but not norovirus capsid protein P domain.

100. The human monoclonal antibody or antibody fragment, or hybridoma or engineered cell producing the same, of claim **97**, wherein said antibody or antibody fragment binds to norovirus capsid protein P domain P1 or P2 subdomain.

101. The human monoclonal antibody or antibody fragment, or hybridoma or engineered cell producing the same, of claim **97**, wherein said antibody or antibody fragment is cross-reactive to multiple norovirus GI and/or GII strains.

* * * * *